<![CDATA[Genmab — November 2013]]>Det er dog helt utroligt så aggressivt ubs, csfb og knight sælger

]]>https://dev.proinvestor.com/forum/topic/451464/genmab-november-2013RSS for NodeThu, 18 Jun 2026 20:58:42 GMTFri, 01 Nov 2013 14:39:23 GMT60<![CDATA[Reply to Genmab — November 2013 on Sat, 30 Nov 2013 09:00:33 GMT]]>Så lige omkring Marts måned eller hvad skal vi tro ??

]]>https://dev.proinvestor.com/forum/post/10073792https://dev.proinvestor.com/forum/post/10073792Sat, 30 Nov 2013 09:00:33 GMT<![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 20:11:11 GMT]]>
  • Oktober sendte GSK ansøgning på Arzerra til FDA
    • ]]>    https://dev.proinvestor.com/forum/post/10073795https://dev.proinvestor.com/forum/post/10073795Fri, 29 Nov 2013 20:11:11 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 20:09:35 GMT]]>4 måneder og 3 dage fra ansøgning til approval på en BLA

    ]]>    https://dev.proinvestor.com/forum/post/10073794https://dev.proinvestor.com/forum/post/10073794Fri, 29 Nov 2013 20:09:35 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 20:08:13 GMT]]>
  • N
    ovember approval
    • ]]>    https://dev.proinvestor.com/forum/post/10073791https://dev.proinvestor.com/forum/post/10073791Fri, 29 Nov 2013 20:08:13 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 20:07:10 GMT]]>
  • August accept
    • ]]>    https://dev.proinvestor.com/forum/post/10073789https://dev.proinvestor.com/forum/post/10073789Fri, 29 Nov 2013 20:07:10 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 20:06:36 GMT]]>10 juli ansøgning

    ]]>    https://dev.proinvestor.com/forum/post/10073793https://dev.proinvestor.com/forum/post/10073793Fri, 29 Nov 2013 20:06:36 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 20:06:21 GMT]]>Vi har haft den på radaren

    ]]>    https://dev.proinvestor.com/forum/post/10073788https://dev.proinvestor.com/forum/post/10073788Fri, 29 Nov 2013 20:06:21 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 17:30:05 GMT]]>vi fik vist ikke markeret denne - http://seekingalpha.com/currents/post/1410482 det er btd kandidat nr 2, der bliver godkendt

    ]]>    https://dev.proinvestor.com/forum/post/10073786https://dev.proinvestor.com/forum/post/10073786Fri, 29 Nov 2013 17:30:05 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 13:52:40 GMT]]>det eneste problem med de resultater er efterhånden, at CR er lidt for høj....

    ]]>    https://dev.proinvestor.com/forum/post/10073784https://dev.proinvestor.com/forum/post/10073784Fri, 29 Nov 2013 13:52:40 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 12:21:47 GMT]]>Det er jo resultater på linie med frontline - ganske pænt i refrac !!!

    ]]>    https://dev.proinvestor.com/forum/post/10073787https://dev.proinvestor.com/forum/post/10073787Fri, 29 Nov 2013 12:21:47 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 10:30:56 GMT]]>Gentogen: jeg er bare ein dumme dänen -:)

    ]]>    https://dev.proinvestor.com/forum/post/10073785https://dev.proinvestor.com/forum/post/10073785Fri, 29 Nov 2013 10:30:56 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 10:30:07 GMT]]>Gentogen: og så på dansk -:)

    ]]>    https://dev.proinvestor.com/forum/post/10073781https://dev.proinvestor.com/forum/post/10073781Fri, 29 Nov 2013 10:30:07 GMT    <![CDATA[Reply to Genmab — November 2013 on Fri, 29 Nov 2013 07:12:45 GMT]]>Ja - arzerra er ikke helt uden virkning

    ]]>    https://dev.proinvestor.com/forum/post/10073783https://dev.proinvestor.com/forum/post/10073783Fri, 29 Nov 2013 07:12:45 GMT    <![CDATA[Reply to Genmab — November 2013 on Thu, 28 Nov 2013 22:41:41 GMT]]>accepted article preview 13 November 2013; doi: 10.1038/leu.2013.334 http://www.nature.com/leu/journal/vaop/naam/abs/leu2013334a.html

    ]]>    https://dev.proinvestor.com/forum/post/10073782https://dev.proinvestor.com/forum/post/10073782Thu, 28 Nov 2013 22:41:41 GMT    <![CDATA[Reply to Genmab — November 2013 on Thu, 28 Nov 2013 22:40:48 GMT]]>BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high risk clinical and biological features.

    ]]>    https://dev.proinvestor.com/forum/post/10073790https://dev.proinvestor.com/forum/post/10073790Thu, 28 Nov 2013 22:40:48 GMT    <![CDATA[Reply to Genmab — November 2013 on Thu, 28 Nov 2013 22:40:06 GMT]]>BendOfa refractory CLL: The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% CI, 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months.

    ]]>    https://dev.proinvestor.com/forum/post/10073775https://dev.proinvestor.com/forum/post/10073775Thu, 28 Nov 2013 22:40:06 GMT    <![CDATA[Reply to Genmab — November 2013 on Wed, 27 Nov 2013 05:13:39 GMT]]>lyder hyggeligt 🙂

    ]]>    https://dev.proinvestor.com/forum/post/10073780https://dev.proinvestor.com/forum/post/10073780Wed, 27 Nov 2013 05:13:39 GMT    <![CDATA[Reply to Genmab — November 2013 on Wed, 27 Nov 2013 05:13:35 GMT]]>Gazyva comes with a boxed warning about the possibility that the Hepatitis B virus could reactivate and it could cause PML (progressive multifocal leukoencephalopathy). PML is a rare brain disorder that damages the material which protects the nerves in the brain.

    ]]>    https://dev.proinvestor.com/forum/post/10073779https://dev.proinvestor.com/forum/post/10073779Wed, 27 Nov 2013 05:13:35 GMT    <![CDATA[Reply to Genmab — November 2013 on Wed, 27 Nov 2013 05:06:51 GMT]]>Var faktisk ikke klar over at vi fik sådanne data

    ]]>    https://dev.proinvestor.com/forum/post/10073774https://dev.proinvestor.com/forum/post/10073774Wed, 27 Nov 2013 05:06:51 GMT    <![CDATA[Reply to Genmab — November 2013 on Wed, 27 Nov 2013 05:06:44 GMT]]>"
    This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)."

    ]]>    https://dev.proinvestor.com/forum/post/10073773https://dev.proinvestor.com/forum/post/10073773Wed, 27 Nov 2013 05:06:44 GMT    <![CDATA[Reply to Genmab — November 2013 on Tue, 26 Nov 2013 19:05:04 GMT]]>ja, det bliver lidt af et landskab at fylde ud. Arzerra + alkylator er ikke taget med i opgørelsen.

    ]]>    https://dev.proinvestor.com/forum/post/10073776https://dev.proinvestor.com/forum/post/10073776Tue, 26 Nov 2013 19:05:04 GMT    <![CDATA[Reply to Genmab — November 2013 on Tue, 26 Nov 2013 18:40:49 GMT]]>https://twitter.com/zDonShimoda/status/405007519640064000/photo/1/large

    ]]>    https://dev.proinvestor.com/forum/post/10073777https://dev.proinvestor.com/forum/post/10073777Tue, 26 Nov 2013 18:40:49 GMT    <![CDATA[Reply to Genmab — November 2013 on Tue, 26 Nov 2013 18:40:08 GMT]]>CLL, competitive landscape. Arzerra er godt med i kombi med ibrutinib og idelalisib https://twitter.com/zDonShimoda/status/405007
    519640064000/photo/1/large

    ]]>    https://dev.proinvestor.com/forum/post/10073778https://dev.proinvestor.com/forum/post/10073778Tue, 26 Nov 2013 18:40:08 GMT    <![CDATA[Reply to Genmab — November 2013 on Tue, 26 Nov 2013 16:42:49 GMT]]>Der bliver varmet om til ASH og det store showdown i CLL markedet - her er lidt baggrund på de forskellige spillere: http://seekingalpha.com/article/1860201-gilead-vs-johnson-johnson-roche-in-blood-cancer-showdown?source=yahoo

    ]]>    https://dev.proinvestor.com/forum/post/10073771https://dev.proinvestor.com/forum/post/10073771Tue, 26 Nov 2013 16:42:49 GMT